



## ***Prism Clinical Imaging and Imaging Biometrics Announce Relationship***

### **Now Offering an Expanded Package of Imaging Tools for Diagnosis and Treatment of Brain Diseases**

Elm Grove, WI, April 20, 2023 – Prism Clinical Imaging, Inc. (Prism), experts in brain mapping software and applications, and Imaging Biometrics, LLC (IB), a provider of quantitative imaging solutions, today announced a partnership to provide a comprehensive package of brain mapping and analysis tools for clinical use in diagnosing brain disease and guiding treatment.

Prism and IB, both with foundational ties to the Medical College of Wisconsin (MCW), each offer specialized clinical solutions for patients with brain tumors and other neurological disorders. Prism provides software and web-based services for acquisition, analysis, and display of functional magnetic resonance imaging (fMRI) and diffusion tensor imaging (DTI) data. It also provides tools to combine fMRI and DTI with other imaging such as PET. These technologies identify critical spatial relationships and functional structures to avoid during treatment, such as surgery. Complementary to fMRI and DTI are IB's MR perfusion, Delta T1, and diffusion applications which provide physiological information critical for diagnosis, treatment, and follow-up of brain tumor patients. Together, Prism's products identify and guide clinicians to the tumor site, then IB's products highlight the most aggressive portions of the tumor key for targeting surgical removal. Together, the combined suite of tools enables the physician to most effectively remove a tumor while maximally preserving brain function.

"The scientific rigor and clinical validation of the Imaging Biometrics tools make them an excellent fit to the Prism Suite's workflow approach," said James L. Reuss, PhD, the CEO of Prism. "IB's quantitative reports and maps will integrate seamlessly with the Brain Imaging Clinical Report generated by Prism's software."

"This agreement makes total sense," said Michael Schmainda, CEO of IB. "Both companies speak to the same clinical teams, and we now can offer them a very complete and comprehensive solution for their patients." Moreover, Schmainda added, "We can now provide this as either a complete user-owned software platform or on a case-by-case online service, whichever best suits the customer's needs."

**About Prism Clinical Imaging® , Inc:** Prism provides clinicians with imaging tools to diagnose and plan treatment for brain disorders including tumors, epilepsy, and other neurological disorders. Deployment options range from on-premises to cloud-based. Please visit [www.prismclinical.com](http://www.prismclinical.com) for further information. Follow Prism on LinkedIn and Twitter, @PrismClinical.

**About Imaging Biometrics® LLC:** IB is a wholly-owned subsidiary of IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at [www.imagingbiometrics.com](http://www.imagingbiometrics.com). Follow IB on Twitter, @IQAI\_IB.